From CNBC: 2024-09-12 09:33:05

Digital health company Noom now offers a compounded GLP-1 drug for weight loss at $149, featuring semaglutide, the same active ingredient in Novo Nordisk’s successful obesity and diabetes drugs. As demand for weight loss and diabetes treatments rises, Noom, Hims & Hers, and Sesame introduce cheaper compounded versions, increasing competition.

The compounded GLP-1 medications provided by Noom are less expensive than brand alternatives like Wegovy and Ozempic, costing around $1,000 monthly. Noom charges $149 for the first month of treatment, with subsequent months priced at $279 as the dose increases. Most insurance plans cover GLP-1s for diabetes but not necessarily for weight loss.

The U.S. FDA does not review compounded products’ safety and efficacy but inspects some facilities. Noom’s program, Noom GLP-1 RX, works with an FDA-regulated 503B compounding pharmacy. The medication taper option allows patients to decide when to stop treatment. Real-world evidence shows some patients can maintain weight loss post-treatment.

Noom offers participants a free year of Noom or discounts if weight is regained after the program. Users fill out an intake form for review by an obesity-trained doctor. Within a week, they receive the medication and guidance on usage, including coaching and psychology-based tools for sustained weight loss. Tapering off the medication is also an option.



Read more at CNBC: Noom to offer GLP-1 drug through new weight loss program